AC Immune (ACIU) Projected to Post Quarterly Earnings on Thursday

AC Immune (NASDAQ:ACIU) is anticipated to announce its Q4 2025 results before the market opens on Thursday, March 12th. Analysts expect the company to announce earnings of ($0.19) per share and revenue of $1.1440 million for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, March 12, 2026 at 12:30 PM ET.

AC Immune Stock Performance

Shares of ACIU opened at $2.84 on Thursday. The stock has a market capitalization of $285.16 million, a PE ratio of -3.38 and a beta of 1.64. The company’s fifty day moving average is $3.19 and its 200 day moving average is $2.99. AC Immune has a fifty-two week low of $1.43 and a fifty-two week high of $4.00.

Analysts Set New Price Targets

A number of analysts have recently weighed in on ACIU shares. Weiss Ratings restated a “sell (d-)” rating on shares of AC Immune in a report on Wednesday, January 21st. Wall Street Zen upgraded AC Immune from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $10.00.

Hedge Funds Weigh In On AC Immune

Hedge funds have recently added to or reduced their stakes in the company. Acadian Asset Management LLC lifted its stake in AC Immune by 87.1% in the first quarter. Acadian Asset Management LLC now owns 371,177 shares of the company’s stock worth $679,000 after purchasing an additional 172,796 shares during the last quarter. Sei Investments Co. bought a new position in shares of AC Immune during the second quarter valued at approximately $51,000. Private Advisor Group LLC purchased a new stake in shares of AC Immune in the third quarter worth approximately $48,000. Susquehanna International Group LLP bought a new stake in shares of AC Immune during the 3rd quarter worth approximately $63,000. Finally, Goldman Sachs Group Inc. boosted its holdings in AC Immune by 46.9% during the 4th quarter. Goldman Sachs Group Inc. now owns 18,555 shares of the company’s stock valued at $58,000 after acquiring an additional 5,920 shares during the period. 51.36% of the stock is currently owned by institutional investors.

AC Immune Company Profile

AC Immune AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates.

Since its founding in 2003, AC Immune has advanced multiple programs into clinical development.